8-fluoro-4-(pyridin-3-yl)-6-{1H-pyrrolo[2,3-b]pyridin-3-yl}quinoline | 2230901-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: 8-fluoro-4-(pyridin-3-yl)-6-{1H-pyrrolo[2,3-b]pyridin-3-yl}quinoline
• 英文别名: 8-fluoro-4-pyridin-3-yl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline
• CAS: 2230901-57-0
• 化学式: C₂₁H₁₃FN₄
• 分子量: 340.359
• InChiKey: UZKNEKQQAVXEOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
  申请人：Felicitex Therapeutics, Inc.

  公开号：US20180179199A1

  公开（公告）日：2018-06-28

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

  本发明涉及化学式（I）的化合物及其盐、立体异构体、互变异构体或N-氧化物。本发明进一步涉及将这种化合物或盐、立体异构体、互变异构体或N-氧化物用作药物的用途，以及包含该化合物的药物组合物。
• Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
  申请人：Felicitex Therapeutics, Inc.

  公开号：US10577365B2

  公开（公告）日：2020-03-03

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

  本发明涉及式（I）化合物及其盐、立体异构体、同分异构体或 N-氧化物。本发明还涉及这种化合物或其盐、立体异构体、同分异构体或 N-氧化物的药物用途以及包含所述化合物的药物组合物。
• DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
  申请人：Felicitex Therapeutics, Inc.

  公开号：EP3558321A1

  公开（公告）日：2019-10-30
• [EN] DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES<br/>[FR] DÉRIVÉS DE QUINOLÉINES EN TANT QU'INHIBITEURS DE KINASES DYRK1A ET/OU DYRK1B
  申请人：FELICITEX THERAPEUTICS INC

  公开号：WO2018119039A1

  公开（公告）日：2018-06-28

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.